A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

October 7, 2020

Study Completion Date

December 21, 2020

Conditions
Myasthenia Gravis
Interventions
DRUG

RVT-1401

Subcutaneous administration of RVT-1401

DRUG

Placebo

Subcutaneous administration of Placebo

Trial Locations (20)

10021

Hospital for Special Surgery, New York

14221

Dent Institute, Amherst

15212

Allegheny Neurological Associates, Pittsburgh

30318

Rare Disease Research, Atlanta

32806

Neurological Services of Orlando, Orlando

36604

IMC/Diagnostic and Medical Clinic, Mobile

55455

University of Minnesota - Department of Neurology, Minneapolis

75390

UTSW James W. Aston Ambulatory Care Center - Neurology Clinic, Dallas

80907

CSNA, Colorado Springs

85018

Phoenix Neurological Associates, Phoenix

91101

Care Access Research, Pasadena

92011

The Neurology Center of Southern California, Carlsbad

92868

UC Irvine - MDA ALS and Neuromuscular Center, Orange

06510

Yale School of Medicine Department of Neurology, New Haven

14260-1660

University of Buffalo, Buffalo

T6G 2G3

University of Alberta Hospitals - Division of Pulmonary Medicine, Edmonton

N6G 2V4

London Health Sciences Centre, London

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

M5G 2C4

University Health Network Toronto General Hospital, Toronto

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Immunovant Sciences GmbH

INDUSTRY

NCT03863080 - A Study of RVT-1401 in Myasthenia Gravis (MG) Patients | Biotech Hunter | Biotech Hunter